4XB Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
XBiotech News
4XB FAQ
What was XBiotech’s price range in the past 12 months?
Currently, no data Available
What is XBiotech’s market cap?
XBiotech’s market cap is CHF56.68M.
When is XBiotech’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were XBiotech’s earnings last quarter?
XBiotech released its earnings results on Mar 14, 2019. The company reported -CHF0.139 earnings per share for the quarter, missing the consensus estimate of N/A by -CHF0.139.
Is XBiotech overvalued?
According to Wall Street analysts XBiotech’s price is currently same.
Does XBiotech pay dividends?
XBiotech does not currently pay dividends.
What is XBiotech’s EPS estimate?
XBiotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XBiotech have?
Currently, no data Available
What happened to XBiotech’s price movement after its last earnings report?
XBiotech reported an EPS of -CHF0.139 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of XBiotech?
Currently, no hedge funds are holding shares in CH:4XB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
XBiotech Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.11%
Trailing 12-Months
Company Description
XBiotech
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
Alterity Therapeutics
―
Immunic
―
Nautilus Biotechnolgy
―
Acumen Pharmaceuticals
―
Invivyd
―